Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways

被引:3
|
作者
Shang, Donghao [1 ]
Li, Gang [2 ]
Zhang, Caixing [1 ]
Liu, Yuting [3 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China
[2] China Med Univ, Liaoning Canc Hosp & Inst, Dept Urol, Canc Hosp, Shenyang 110042, Liaoning, Peoples R China
[3] Capital Med Univ, Dept Pathol, Beijing 100069, Peoples R China
关键词
urothelial carcinoma; DAC; CDDP; TGFBI; MAPK; 5-AZA-2'-DEOXYCYTIDINE ENHANCES SUSCEPTIBILITY; TRANSITIONAL-CELL CARCINOMA; DNA METHYLATION; PROMOTER METHYLATION; BREAST-CANCER; BLADDER; AGENT; DECITABINE; EXPRESSION; PACLITAXEL;
D O I
10.1139/bcb-2021-0277
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to reveal the gene transcriptional alterations, possible molecular mechanisms, and pathways and T24, were used in the present study. A cDNA microarray was performed to identify critical genes involved in the synergistic mechanism of both agents against UC cells. The results showed that several key regulatory genes, such as interleukin 24 (IL24), fibroblast growth factor 1 (FGF1), and transforming growth factor beta induced (TGFBI), may play critical roles in the synergy of DAC and CDDP in UC. Pathway enrichment suggested that many carcinogenesis-related pathways, such as the ECM-receptor interaction and MAPK signaling pathways, may participate in the synergy of both agents. Our results suggest that TGF-I31 stimulates the phosphorylation of ERK1/2 and p38 by increasing TGFBI expression, and that the TGFBI-MAPK signaling pathway plays an important role in the synergy of DAC and CDDP against UC. Therefore, we revealed the synergistic mechanism of DAC and CDDP in UC. Several key regulatory genes play critical roles in the synergy of combined treatment, and the TGFBI-MAPK signaling pathway may be an important potential target of these two agents.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 48 条
  • [31] Restoration of expression of transforming growth factor-ß type II receptor in murine renal cell carcinoma (Renca) cells by 5-aza-2′-deoxycytidine
    Zhang, Q
    Rubenstein, JN
    Jang, TL
    Park, I
    Lee, C
    JOURNAL OF UROLOGY, 2005, 173 (04): : 174 - 174
  • [32] Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2′-deoxycytidine-triggered invasiveness
    Cheishvili, David
    Chik, Flora
    Li, Chen Chen
    Bhattacharya, Bishnu
    Suderman, Matthew
    Arakelian, Ani
    Hallett, Michael
    Rabbani, Shafaat A.
    Szyf, Moshe
    CARCINOGENESIS, 2014, 35 (11) : 2436 - 2446
  • [33] AML1/ETO expression in myeloid leukemia cells is associated with enhanced growth-inhibitory and P15/INK4b demethylating effects of 5-aza-2′-deoxycytidine.
    Berg, T
    Abdelkarim, M
    Guo, Y
    Fliegauf, M
    Lübbert, M
    BLOOD, 2004, 104 (11) : 330A - 330A
  • [34] Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling
    Takano, Y.
    Iwata, H.
    Yano, Y.
    Miyazawa, M.
    Virgona, N.
    Sato, H.
    Ueno, K.
    Yano, T.
    BIOCHEMICAL PHARMACOLOGY, 2010, 80 (04) : 463 - 470
  • [35] The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine
    Alleman, WG
    Tabios, RL
    Chandramouli, GVR
    Aprelikova, ON
    Torres-Cabala, C
    Mendoza, A
    Rodgers, C
    Sopko, NA
    Linehan, WM
    Vasselli, JR
    CLINICAL CANCER RESEARCH, 2004, 10 (20) : 7011 - 7021
  • [36] Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
    Xiong, Jingbo
    Epstein, Richard J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) : 779 - 785
  • [37] Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2′-deoxycytidine (AZA) in breast cancer cells
    Zeng, Li
    Jarrett, Caroline
    Brown, Keith
    Gillespie, Kathleen M.
    Holly, Jeff M. P.
    Perks, Claire M.
    EXPERIMENTAL CELL RESEARCH, 2013, 319 (14) : 2282 - 2295
  • [38] Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway
    Son, Dong Ju
    Hong, Ji Eun
    Ban, Jung Ok
    Park, Ju Ho
    Lee, Hye Lim
    Gu, Sun Mi
    Hwang, Jae Yeon
    Jung, Myung Hee
    Lee, Dong Won
    Han, Sang-Bae
    Hong, Jin Tae
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [39] Effects of 5-aza-2′-deoxycytidine and Valproic Acid on Epigenetic-modifying DNMT1 Gene Expression, Apoptosis Induction and Cell Viability in Hepatocellular Carcinoma WCH-17 cell line
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2019, 9 (02) : 83 - 90
  • [40] Inhibitory effect of taspine derivative TAD1822-7 on tumor cell growth and angiogenesis via suppression of EphrinB2 and related signaling pathways
    Liu, Rui
    Yu, Runze
    Cui, Yuxin
    Fan, Mengying
    Wang, Bo
    Zhang, Yanmin
    ACTA PHARMACEUTICA, 2019, 69 (03) : 423 - 431